NewGenIvf Group Announces Update On Proposed Reverse Merger With COVIRIX Medical; Due Diligence Progressing, Anticipated Completion By End Of August 2024; COVIRIX Engages U.S. University For Antiviral Drug Study, Holds 80K Zucoins In Treasury
Portfolio Pulse from Benzinga Newsdesk
NewGenIvf Group has provided an update on its proposed reverse merger with COVIRIX Medical. The due diligence process is progressing, and the merger is anticipated to be completed by the end of August 2024. Additionally, COVIRIX has engaged a U.S. university for an antiviral drug study and holds 80,000 Zucoins in its treasury.
July 23, 2024 | 8:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NewGenIvf Group's reverse merger with COVIRIX Medical is progressing, with completion expected by August 2024. This merger could significantly impact NIVF's market position and valuation.
The reverse merger with COVIRIX Medical is a significant corporate action that could enhance NewGenIvf Group's market position and valuation. The progress in due diligence and the anticipated completion date provide a clear timeline for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100